Newly Appointed Board Chair, Philip Astley-Sparke, Brings Transatlantic Late-Stage Development, Regulatory and Commercial Expertise
Strengthened Leadership and Expanded U.S. Presence Positions SynOx for Regulatory Filings and Commercialization of Emactuzumab for Tenosynovial Giant Cell Tumours (TGCT)
DUBLIN, IRELAND and OXFORD, UK, April 1, 2025 – SynOx Therapeutics Limited (“SynOx”), a late-stage clinical biopharmaceutical company developing of emactuzumab for Tenosynovial Giant Cell Tumours (TGCT), today announced the execution of a planned and orderly transition of its board chair position. Philip Astley-Sparke has been appointed as new chair of the board of directors, reflecting SynOx’s ongoing evolution into a global, commercially focused biotechnology company. Mr. Astley-Sparke succeeds Ton Logtenberg, who has served as board chair since 2021, overseeing the company’s growth into a well-funded, late-stage clinical company.
With its Phase 3 registrational trial of emactuzumab in TGCT underway, SynOx has evolved its strategic focus to prioritize global regulatory filings, commercial readiness and increasing its transatlantic footprint. This builds upon recent corporate milestones including the raising of a $92 million Series B round of funding and the ongoing build-out of its US executive leadership team.
“Ton has been a steady and invaluable partner through a critical period of growth and maturation for SynOx and we are deeply indebted to him for his leadership over the past several years,” said Ray Barlow, Chief Executive Officer of SynOx Therapeutics. “As we embark on our next phase focused on regulatory and commercial activities, we are happy to welcome Philip as our new board chair. His proven experience leading late-stage, transatlantic companies and guiding assets through regulatory approval and launch preparedness will be pivotal as we prepare for the potential commercialization of emactuzumab.”
Mr. Astley-Sparke is a seasoned biotechnology executive with a distinguished track record in building and leading innovative companies across immuno-oncology and rare diseases. With over two decades of experience, he has successfully guided multiple organizations from early-stage through to BLA filing with the United States Food and Drug Administration (FDA) and accompanying commercial launch preparations. He has raised over $1.5 billion in capital and held key leadership roles at Replimune Group Inc, where he currently serves as Executive Chairman, uniQure N.V, and BioVex Group Inc. Notably, at BioVex he played a central role in the development of the first FDA-approved oncolytic virus and oversaw a $1 billion acquisition by Amgen. Mr. Astley-Sparke provides SynOx deep expertise in transatlantic biotech operations, in-house manufacturing scale-up, execution of initial public offerings (IPOs), and strategic growth.
For the full press release see here: SynOx Tx_Chair transition PR
